{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T14:53:14Z","timestamp":1791211994884,"version":"4.1.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,5]]},"DOI":"10.7759\/cureus.117479","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T14:08:45Z","timestamp":1791209325000},"source":"Crossref","is-referenced-by-count":0,"title":["Real-World Effectiveness, Safety, and Tolerability of Adjuvant CDK4\/6 Inhibitor Therapy"],"prefix":"10.7759","author":[{"given":"Kajal","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harsha P","family":"Panchal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apurva","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajan","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.4837","article-title":"Global stage distribution of breast cancer at diagnosis: a systematic review and meta-analysis","volume":"10","author":"Benitez Fuentes JD","year":"2024","unstructured":"Benitez Fuentes JD, Morgan E, de Luna Aguilar A, et al.. Global stage distribution of breast cancer at diagnosis: a systematic review and meta-analysis. JAMA Oncol. 2024, 10:71-8. 10.1001\/jamaoncol.2023.4837","journal-title":"JAMA Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)61074-1","article-title":"Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials","volume":"386","author":"Early Breast Cancer Trialists' Collaborative Group (EBCTCG)","year":"2015","unstructured":"Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015, 386:1341-52. 10.1016\/S0140-6736(15)61074-1","journal-title":"Lancet"},{"key":"ref3","unstructured":"NCCN Guidelines. breast cancer\r\n. (2026). Accessed: 2026: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1419."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00694-5","article-title":"Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial","volume":"24","author":"Johnston SR","year":"2023","unstructured":"Johnston SR, Toi M, O'Shaughnessy J, et al.. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023, 24:77-90. 10.1016\/S1470-2045(22)00694-5","journal-title":"Lancet Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01994","article-title":"Adjuvant abemaciclib plus endocrine therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative, high-risk early breast cancer: results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes","volume":"42","author":"Rastogi P","year":"2024","unstructured":"Rastogi P, O'Shaughnessy J, Martin M, et al.. Adjuvant abemaciclib plus endocrine therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative, high-risk early breast cancer: results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes. J Clin Oncol. 2024, 42:987-93. 10.1200\/JCO.23.01994","journal-title":"J Clin Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2305488","article-title":"Ribociclib plus endocrine therapy in early breast cancer","volume":"390","author":"Slamon D","year":"2024","unstructured":"Slamon D, Lipatov O, Nowecki Z, et al.. Ribociclib plus endocrine therapy in early breast cancer. N Engl J Med. 2024, 390:1080-91. 10.1056\/NEJMoa2305488","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02554","article-title":"Adjuvant palbociclib for early breast cancer: the PALLAS trial results (ABCSG-42\/AFT-05\/BIG-14-03)","volume":"40","author":"Gnant M","year":"2022","unstructured":"Gnant M, Dueck AC, Frantal S, et al.. Adjuvant palbociclib for early breast cancer: the PALLAS trial results (ABCSG-42\/AFT-05\/BIG-14-03). J Clin Oncol. 2022, 40:282-93. 10.1200\/JCO.21.02554","journal-title":"J Clin Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03639","article-title":"Palbociclib for residual high-risk invasive HR-positive and HER2-negative early breast cancer\u2014the PENELOPE-B trial","volume":"39","author":"Loibl S","year":"2021","unstructured":"Loibl S, Marm\u00e9 F, Martin M, et al.. Palbociclib for residual high-risk invasive HR-positive and HER2-negative early breast cancer\u2014the PENELOPE-B trial. J Clin Oncol. 2021, 39:1518-30. 10.1200\/JCO.20.03639","journal-title":"J Clin Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2025.3700","article-title":"Ribociclib plus endocrine therapy in hormone receptor-positive\/ERBB2-negative early breast cancer: 4-year outcomes from the NATALEE randomized clinical trial","volume":"11","author":"Fasching PA","year":"2025","unstructured":"Fasching PA, Stroyakovskiy D, Yardley DA, et al.. Ribociclib plus endocrine therapy in hormone receptor-positive\/ERBB2-negative early breast cancer: 4-year outcomes from the NATALEE randomized clinical trial. JAMA Oncol. 2025, 11:1364-72. 10.1001\/jamaoncol.2025.3700","journal-title":"JAMA Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2024.2346464","article-title":"Real-world data on patients with early breast cancer who were prescribed abemaciclib adjuvant therapy in Japan","volume":"20","author":"Shimoi T","year":"2024","unstructured":"Shimoi T, Pathadka S, Sekine N, et al.. Real-world data on patients with early breast cancer who were prescribed abemaciclib adjuvant therapy in Japan. Future Oncol. 2024, 20:2179-88. 10.1080\/14796694.2024.2346464","journal-title":"Future Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1177\/10781552241279189","article-title":"Real-world experience of abemaciclib for adjuvant and metastatic breast cancer","volume":"31","author":"Drowne T","year":"2025","unstructured":"Drowne T, Armgardt E, Svoboda A. Real-world experience of abemaciclib for adjuvant and metastatic breast cancer. J Oncol Pharm Pract. 2025, 31:141-6. 10.1177\/10781552241279189","journal-title":"J Oncol Pharm Pract"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/533310-real-world-effectiveness-safety-and-tolerability-of-adjuvant-cdk46-inhibitor-therapy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T14:08:46Z","timestamp":1791209326000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/533310-real-world-effectiveness-safety-and-tolerability-of-adjuvant-cdk46-inhibitor-therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,5]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.117479","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10,5]]}}}